Living-donor kidney transplant from hepatitis B surface antigen-positive donors to hepatitis B antibody-positive recipients without hepatitis B immunoglobulin prophylaxis in an endemic country

Heungman Jun, Myung-Gyu Kim, Kwan Tae Park, Cheol Woong Jung

Research output: Contribution to journalArticle

Abstract

Objectives: Living-donor kidney transplant from donors who are chronically infected with hepatitis B virus can be considered as a possibility to compensate for insufficiency of organ transplants, particularly in a hepatitis B virus endemic country. In this study, the safety and efficacy were reviewed retrospectively in living-donor kidney transplant from donors who were chronically infected with hepatitis B virus. Materials and Methods: In the years between 2012 and 2013, we transplanted 4 renal grafts from hepatitis B surface antigen-positive living donors to antihepatitis B antibody-positive recipients. Lamivudine was prescribed for recipients after transplant without hepatitis B immuno globulin. Results: In 1-year follow-up, there were no abnormal findings in the levels of renal and liver enzymes, and there was no unwanted seroconversion to positive hepatitis B surface antigen. Conclusions: When combined with careful hepatitis B virus-monitoring, renal grafts from hepatitis B surface antigen-positive living donors can be transplanted to hepatitis B antibody-positive recipients, without the need for hepatitis B immunoglobulin prophylaxis, in a hepatitis B virus endemic country.

Original languageEnglish
Pages (from-to)256-258
Number of pages3
JournalExperimental and Clinical Transplantation
Volume13
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Hepatitis B Antibodies
Living Donors
Hepatitis B Surface Antigens
Hepatitis B
Hepatitis B virus
Immunoglobulins
Tissue Donors
Transplants
Kidney
Lamivudine
Globulins
Safety
Antibodies
Liver
Enzymes

Keywords

  • End-stage renal disease
  • Infectious diseases
  • Lamivudine

ASJC Scopus subject areas

  • Transplantation

Cite this

@article{86d14e10927d423d91109c67813b40f2,
title = "Living-donor kidney transplant from hepatitis B surface antigen-positive donors to hepatitis B antibody-positive recipients without hepatitis B immunoglobulin prophylaxis in an endemic country",
abstract = "Objectives: Living-donor kidney transplant from donors who are chronically infected with hepatitis B virus can be considered as a possibility to compensate for insufficiency of organ transplants, particularly in a hepatitis B virus endemic country. In this study, the safety and efficacy were reviewed retrospectively in living-donor kidney transplant from donors who were chronically infected with hepatitis B virus. Materials and Methods: In the years between 2012 and 2013, we transplanted 4 renal grafts from hepatitis B surface antigen-positive living donors to antihepatitis B antibody-positive recipients. Lamivudine was prescribed for recipients after transplant without hepatitis B immuno globulin. Results: In 1-year follow-up, there were no abnormal findings in the levels of renal and liver enzymes, and there was no unwanted seroconversion to positive hepatitis B surface antigen. Conclusions: When combined with careful hepatitis B virus-monitoring, renal grafts from hepatitis B surface antigen-positive living donors can be transplanted to hepatitis B antibody-positive recipients, without the need for hepatitis B immunoglobulin prophylaxis, in a hepatitis B virus endemic country.",
keywords = "End-stage renal disease, Infectious diseases, Lamivudine",
author = "Heungman Jun and Myung-Gyu Kim and Park, {Kwan Tae} and Jung, {Cheol Woong}",
year = "2015",
month = "1",
day = "1",
doi = "10.6002/ect.mesot2014.P60",
language = "English",
volume = "13",
pages = "256--258",
journal = "Experimental and Clinical Transplantation",
issn = "1304-0855",
publisher = "Baskent University",

}

TY - JOUR

T1 - Living-donor kidney transplant from hepatitis B surface antigen-positive donors to hepatitis B antibody-positive recipients without hepatitis B immunoglobulin prophylaxis in an endemic country

AU - Jun, Heungman

AU - Kim, Myung-Gyu

AU - Park, Kwan Tae

AU - Jung, Cheol Woong

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Objectives: Living-donor kidney transplant from donors who are chronically infected with hepatitis B virus can be considered as a possibility to compensate for insufficiency of organ transplants, particularly in a hepatitis B virus endemic country. In this study, the safety and efficacy were reviewed retrospectively in living-donor kidney transplant from donors who were chronically infected with hepatitis B virus. Materials and Methods: In the years between 2012 and 2013, we transplanted 4 renal grafts from hepatitis B surface antigen-positive living donors to antihepatitis B antibody-positive recipients. Lamivudine was prescribed for recipients after transplant without hepatitis B immuno globulin. Results: In 1-year follow-up, there were no abnormal findings in the levels of renal and liver enzymes, and there was no unwanted seroconversion to positive hepatitis B surface antigen. Conclusions: When combined with careful hepatitis B virus-monitoring, renal grafts from hepatitis B surface antigen-positive living donors can be transplanted to hepatitis B antibody-positive recipients, without the need for hepatitis B immunoglobulin prophylaxis, in a hepatitis B virus endemic country.

AB - Objectives: Living-donor kidney transplant from donors who are chronically infected with hepatitis B virus can be considered as a possibility to compensate for insufficiency of organ transplants, particularly in a hepatitis B virus endemic country. In this study, the safety and efficacy were reviewed retrospectively in living-donor kidney transplant from donors who were chronically infected with hepatitis B virus. Materials and Methods: In the years between 2012 and 2013, we transplanted 4 renal grafts from hepatitis B surface antigen-positive living donors to antihepatitis B antibody-positive recipients. Lamivudine was prescribed for recipients after transplant without hepatitis B immuno globulin. Results: In 1-year follow-up, there were no abnormal findings in the levels of renal and liver enzymes, and there was no unwanted seroconversion to positive hepatitis B surface antigen. Conclusions: When combined with careful hepatitis B virus-monitoring, renal grafts from hepatitis B surface antigen-positive living donors can be transplanted to hepatitis B antibody-positive recipients, without the need for hepatitis B immunoglobulin prophylaxis, in a hepatitis B virus endemic country.

KW - End-stage renal disease

KW - Infectious diseases

KW - Lamivudine

UR - http://www.scopus.com/inward/record.url?scp=84939813634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939813634&partnerID=8YFLogxK

U2 - 10.6002/ect.mesot2014.P60

DO - 10.6002/ect.mesot2014.P60

M3 - Article

VL - 13

SP - 256

EP - 258

JO - Experimental and Clinical Transplantation

JF - Experimental and Clinical Transplantation

SN - 1304-0855

ER -